Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Chemed (CHE) and PROCEPT BioRobotics (PRCT)

Tipranks - Tipranks - Mon Mar 23, 7:50AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK), Chemed (CHE) and PROCEPT BioRobotics (PRCT) with bullish sentiments.

Claim 30% Off TipRanks Premium

Merck & Company (MRK)

In a report issued on March 20, Mohit Bansal from Wells Fargo maintained a Buy rating on Merck & Company, with a price target of $150.00. The company’s shares closed last Friday at $114.18.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.2% and a 55.6% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Travere Therapeutics. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $131.41, a 15.0% upside from current levels. In a report issued on March 5, J.P. Morgan also maintained a Buy rating on the stock with a $125.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Chemed (CHE)

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed on March 20. The company’s shares closed last Friday at $377.99.

According to TipRanks.com, Wiederhorn is a 5-star analyst with an average return of 9.2% and a 57.7% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, The Ensign Group, and Community Health. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Chemed with a $424.00 average price target.

PROCEPT BioRobotics (PRCT)

In a report issued on March 20, Nathan Treybeck from Wells Fargo maintained a Buy rating on PROCEPT BioRobotics, with a price target of $34.00. The company’s shares closed last Friday at $25.79.

Treybeck has an average return of 12.3% when recommending PROCEPT BioRobotics. ;'>

According to TipRanks.com, Treybeck is ranked #9044 out of 12128 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PROCEPT BioRobotics with a $35.22 average price target, implying a 35.7% upside from current levels. In a report issued on March 13, TD Cowen also maintained a Buy rating on the stock with a $34.00 price target.

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).